Major adverse cardiac and cerebrovascular events (MACCE)(double-arm randomised and observational studies)
Comparing the data of two randomised control studies12,13 with a total of 269 patients, we noted no significant difference in the rates of MACCE associated with the use of FFR-guided CABG as compared to CAG-guided CABG (RR: 0.89, 95% CI: 0.41 to 1.94, p = 0.77) (Figure 2B). Data analysis of two observational studies14,15 and 1023 patients showed no significant difference in the rates of MACCE with the use of FFR-guided CABG or CAG-guided CABG (RR: 0.85, 95% CI: 0.64 to 1.12, p =0.25) (Figure 2B). The results of all four studies with a total of 1292 patients ultimately showed no difference in the rates of MACCE in the FFR-guided CABG group as compared to the conventional CAG-guided CABG group (RR: 0.85, 95% CI: 0.65 to 1.11, p = 0.23) (Figure 2B).